Lophora is a drug-development start-up developing new rapid-acting drugs for central nervous system diseases including treatment-resistant depression.
Founded in 2017 Lophora has successfully finished initial characterization of our lead-candidate through PoC funding granted by the BioInovation institute and plan to begin first in human trials by 2022.
We believe we hold a unique position in the market for anti-depressant therapies of the future. The company seeks to mature lead-candidate LPH-5 through pre-clinical operations, toward IND status by the end of 2021. Given our unique technology and knowledge of the field, we are confident that we are moving ahead of a global market shift towards medically aided psychotherapy as a treatment for CNS disorders.
Interested in the antidepressant therapy of the future?
Get in Touch
Lophora is currently located at the BioInnovation Institute at COBIS Copenhagen.
Invested in bringing relief from despair